Europe Veterinary Pharmaceuticals Market Report: Market Size & Forecast 2026

The European veterinary pharmaceuticals market covers prescription and over-the-counter drugs, biologics, and APIs formulated for both food-producing animals and companion animals. With a 2025 valuation near USD 17.46 billion and an 8.45% CAGR, the market is on track to surpass USD 16 billion-USD 30 billion by the early-to-mid 2030s, depending on the forecast horizon used. Europe remains one of the most mature and heavily regulated veterinary drug markets globally, anchored by a large livestock base in countries such as France, Germany, Spain, the UK, Italy, and the Netherlands, alongside high companion-animal spending in Western and Northern Europe.

• •2025 market size: approximately USD 17.46 billion, with projected CAGR of 8.45%.
• •Demand spans both food-producing animals (cattle, swine, poultry) and companion animals (dogs, cats, horses).
• •Strong regulatory framework under the European Medicines Agency and EU veterinary medicines legislation shapes product approvals and market entry.

Rising pet ownership and the willingness of European owners to spend on advanced veterinary care are expanding the companion-animal therapeutics segment. At the same time, pressure to meet stringent food-safety and animal-welfare standards is pushing livestock producers toward preventive medicines, vaccines, and parasiticides. Consolidation of European livestock farming and growing concerns over zoonotic diseases and antimicrobial resistance are also accelerating the adoption of modern veterinary pharmaceuticals.

• •Humanization of pets is lifting per-animal spending on chronic-disease treatments, oncology, and dermatology drugs.
• •Livestock intensification and export-oriented meat and dairy production drive demand for vaccines, anti-infectives, and reproductive hormones.
• •Heightened focus on antimicrobial stewardship is shifting usage toward vaccines, parasiticides, and non-antibiotic alternatives.

By product type, the market is typically split into pharmaceuticals (anti-infectives, parasiticides, anti-inflammatories, hormones, and others) and biologics such as vaccines. By animal type, livestock species historically account for the largest revenue share, while companion animals represent the fastest-growing segment. Geographically, Western Europe leads the market, with Germany, France, the UK, Spain, and Italy contributing the bulk of revenues, while Central and Eastern Europe are emerging as higher-growth regions.

• •Pharmaceuticals (anti-infectives, parasiticides, anti-inflammatories) constitute the largest product category, with vaccines growing quickly.
• •Companion animals are the fastest-expanding segment, though livestock remains the largest by absolute revenue.
• •Western European countries dominate spending, while Eastern Europe shows faster percentage growth as incomes and pet ownership rise.

What are the recent trends and outlook?

Key trends shaping the market through the next decade include the development of monoclonal antibodies and other advanced biologics for companion animals, growing investment in preventive healthcare, and digital tools that support compliance and treatment monitoring. Regulatory pressure to phase out certain antibiotics in livestock is expected to accelerate demand for vaccines and alternative therapies. Overall, the market outlook remains robust, supported by structural demand from both pet owners and commercial livestock operations.

• •Innovation in long-acting injectables, monoclonal antibodies, and parasiticides is expanding the addressable market in companion animals.
• •Tightening EU rules on antibiotic use are redirecting livestock spending toward vaccines, diagnostics, and non-antibiotic alternatives.
• •E-commerce and digital veterinary channels are improving drug accessibility, particularly for routine parasiticides and chronic-disease medications.